| Drug Name |
Imatinib |
| Drug ID |
BADD_D01136 |
| Description |
Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies.
It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells. |
| Indications and Usage |
For the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST). |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
L01EA01 |
| DrugBank ID |
DB00619
|
| KEGG ID |
D08066
|
| MeSH ID |
D000068877
|
| PubChem ID |
5291
|
| TTD Drug ID |
D0AZ3C
|
| NDC Product Code |
65162-795; 51407-270; 63850-4826; 68180-391; 65162-794; 42292-043; 0378-2246; 68554-0034; 43598-344; 51407-269; 42292-044; 48087-0143; 43598-345; 0378-2245; 68180-390 |
| Synonyms |
Imatinib Mesylate | Mesylate, Imatinib | Imatinib Methanesulfonate | Methanesulfonate, Imatinib | STI571 | STI-571 | STI 571 | Gleevec | Glivec | ST 1571 | ST1571 | CGP 57148 | CGP57148B | CGP-57148 | CGP57148 | Imatinib | Alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide |
